SCHEMBL98162

SCHEMBL98162

CCOC(=O)C(Cl)c1ccc(OC)c2c1ccc(=O)n2C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 4/20 0.39
NQO2 P16083 4/20 0.39
LMNA P02545 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
RXFP1 Q9HBX9 1/20 0.36
ALDH1A1 P00352 6/20 0.35
GLA P06280 1/20 0.35
PKM P14618 1/20 0.35
HPGD P15428 1/20 0.35
KMT2A Q03164 2/20 0.35
TNF P01375 2/20 0.34
TSHR P16473 3/20 0.33
CYP1A2 P05177 2/20 0.33
CYP3A4 P08684 2/20 0.33
CYP2C19 P33261 2/20 0.33
CYP2C9 P11712 1/20 0.33
ALOX15 P16050 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MAPK1 P28482 1/20 0.33
BLM P54132 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL97980 0.78 ALDH1A1 (0.41) CYP19A1NQO2LMNASMN1; SMN2RXFP1
SCHEMBL97855 0.76 CYP19A1 (0.38) CYP19A1NQO2LMNASMN1; SMN2RXFP1
SCHEMBL97251 0.74 L3MBTL1 (0.40) CYP19A1NQO2LMNASMN1; SMN2ALDH1A1
SCHEMBL98449 0.73 CYP19A1 (0.39) CYP19A1NQO2RXFP1ALDH1A1HPGD
SCHEMBL98475 0.73 CYP19A1 (0.37) CYP19A1NQO2LMNARXFP1ALDH1A1
SCHEMBL96460 0.72 MAPT (0.54) CYP19A1NQO2LMNASMN1; SMN2RXFP1
SCHEMBL98644 0.72 KMT2A (0.46) CYP19A1NQO2RXFP1ALDH1A1KMT2A
SCHEMBL98053 0.71 CYP19A1 (0.36) CYP19A1NQO2LMNASMN1; SMN2RXFP1
SCHEMBL14438070 0.71 CYP19A1 (0.61) CYP19A1NQO2SMN1; SMN2ALDH1A1GLA
SCHEMBL96811 0.70 KMT2A (0.38) CYP19A1NQO2RXFP1ALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 CYP19A1 2763/4885NQO2 2030/4885LMNA 4860/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 CYP19A1 2763/4885NQO2 2030/4885LMNA 4860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.